Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3

Interventions

Carboplatin 12pembrolizumab 11Gemcitabine 10Cisplatin 10Rituximab 7Pemetrexed 6Nivolumab 6osimertinib 5durvalumab 5atezolizumab 5Specimen Handling 5Paclitaxel 5Dexamethasone 5trastuzumab deruxtecan 4amivantamab 4Prednisone 4Ipilimumab 4Cyclophosphamide 4Capecitabine 4Bortezomib 4tremelimumab 3niraparib 3lazertinib 3entrectinib 3daratumumab 3belzutifan 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × lazertinib × 90 days × Clear all
NCT02609776 2026-05-08

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting
751 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡